How to search for a Pharmacy or Drug using the Express Scripts website
|
|
- Tiffany Chapman
- 6 years ago
- Views:
Transcription
1 How to search for a Pharmacy or Drug using the Express Scripts website You are able to look for a participating pharmacy or a particular drug using the following website: Search for a Pharmacy Click on the Find a local participating pharmacy tab. Enter the zip code or city and state that you are inquiring about and click the locate pharmacy tab. This will show a list of pharmacies in the area that participate with Express Scripts. Helpful tip: If searching by city and state be sure to use a comma between the city and state name. See below for a sample screen shot of pharmacy results: Search for a Prescription Drug
2 Click on the Formulary look up drugs by name tab. You can then 1) search by name, 2) search alphabetically or 3) search by treatment category. If you find the drug s name that you are inquiring about click on it and that will take you to information on the drug which also provides the Status and Medication Type. Status is where you ll find whether the drug is preferred or non-preferred and Medication Type is where you ll find whether the drug is generic or brand. Although tier information is not listed, this is how to interpret which tier drugs are covered under: Tier 1 products are now called Generic Tier 2 products are now called Preferred Brands Tier 3 is now called Non-Preferred Brands Tier 4 co-payment will not show up as Tier 4 on the web. Please use the list attached below to compare. If a drug is not found that indicates that it is not covered See below for a sample screen shot of drug results: It s important to note that some medications may move from one tier to another. Depending on whether the medication is moving to a higher or lower tier, the amount you pay for that medication may increase or decrease. Express Scripts makes updates to its preferred drug list on an ongoing basis.
3 Specialty Drug List Unless otherwise noted, all brand and generic formulations of a product are considered specialty. Green = Drugs distributed exclusively by Accredo. Red = Drugs distributed by Accredo as part of a limited distribution network. Blue = Drugs that are designated specialty but not dispensed by Accredo. * = Your plan may require most specialty medications to be dispensed exclusively by Accredo. Those medications marked by an asterisk (*) may have allowances for one or more retail fills. ALPHA 1 DEFICIENCY Aralast NP * Glassia TM * Zemaira * Prolastin C ANTICOAGULANT Arixtra * (fondaparinux CANCER (cont d) Jevtana Kadcyla TM Kepivance Keytruda Kyprolis Lenvima TM Lupron Depot CYSTIC FIBROSIS Bethkis * Cayston Kalydeco TM * Kitabis Pak TM Pulmozyme * Tobi (tobramycin) Tobi Podhaler TM HEMOPHILIA (cont d) Helixate FS Hemofil M Humate-P Ixinity Koate- DVI Kogenate FS Monoclate-P HIV (Cont d) Selzentry * Stribild * Tivicay * Triumeq * Trizivir *(abacavir, lamivudine, and zidovudine) Truvada * sodum) Lynparza TM Mononine Tybost * Ple Fragmin * Iprivask Lovenox *(enoxaparin sodium) ASTHMA & ALLERGY Xolair Oralair BLOOD CELL DEFICIENCY Aranesp Mircera Epogen Granix TM Leukine Mozobil Neulasta Neumega Neupogen Nplate Procrit Promacta CANCER Abraxane Adcetris TM Afinitor Arranon Arzerra Avastin Marqibo Matulane Mekinist TM Nexavar Opdivo Perjeta TM Pomalyst Proleukin Prothelial TM Provenge Purixan TM Revlimid Rituxan Sprycel Stivarga Sutent Sylatron TM Sylvant TM Synribo TM Tafinlar Tarceva Targretin Tasigna Temodar (temozolomide) Testopel Thalomid Thyrogen Torisel Treanda Tykerb Valchlor TM Valstar ENDOCRINE DISORDERS Aveed TM Korlym Kuvan Lupaneta Pack TM Lupron Depot-Ped Natpara Ruconest Samsca Sandostatin (octreotide acetate) Sandostatin LAR Signifor Somatuline Depot Somatuline Depot Somavert Supprelin LA ENZYME DEFICIENCY Adagen Aldurazyme Carbaglu Cerdelga TM Cerezyme Elaprase Elelyso TM Fabrazyme Lumizyme TM Myozyme Naglazyme Orfadin Sucraid Novoeight Novoseven RT Obizur TM Profilnine SD Recombinate TM RiaSTAP Rixubis TM Stimate Tretten Wilate Xyntha HEPATITIS C Harvoni Infergen Olysio TM Pegasys Peg- Intron Ribavirin (Rebetol, Copegus, Ribasphere, Ribapak, Ribavirin (Moderiba TM ) Sovaldi TM Victrelis TM Viekira Pak TM HEREDITARY ANGIOEDEMA Berinert * Cinryze * Firazyr * Kalbitor * Beleodaq TM Vantas Blincyto TM Vectibix VPRIV TM Ruconest * Vimizim TM Bosulif Velcade Zavesca HIV Bravelle Caprelsa Vidaza (azacitidine Aptivus * Cometriq TM Votrient ) GROWTH DEFICIENCY Atripla * Xalkori Xeloda (capecitabine) Genotropin Xgeva TM Humatrope Xofigo Xtandi Increlex Yervoy TM Zaltrap Norditropin Nutropin Zarxio TM Zelboraf TM AQ Omnitrope Zoladex Zolinza Saizen Serostim Zometa Zydelig Zomacton Zorbtive Zykadia TM Zytiga TM Videx * (didanosine) Videx EC *(didanosine DR) Viracept * Viramune * (nevirapine) Viramune XR *(nevirapine ER) Viread * Vitekta * Zerit * (stavudine) Ziagen *(abacavir) IDIOPATHIC PULMONARY FIBROSIS Esbriet TM OFEV IMMUNE DEFICIENCY Actimmune Bivigam TM Carimune NF Cytogam Flebogamma Gamastan S-D Gammagard Liquid Gammagard S-D Gammaked TM Gammaplex Gamunex-C Hizentra TM Hyqvia Octagam Privigen Cetrotide Chorionic Gonadatropin (brands Crinone Cyramza TM Dacogen (decitabine) Eligard Erbitux Erivedge TM Erwinaze Firmagon Folotyn Gazyva TM Gilotrif TM Gleevec Halaven TM Herceptin Hycamtin (capsules) Hycamtin (topotecan injection) Ibrance Iclusig Imbruvica TM Inlyta Intron A Istodax Ixempra Jakafi TM CONTRACEPTIVE Liletta TM Mirena Nexplanon Paragard Skyla HEMOPHILIA Advate Alphanate Alphanine SD Alprolix TM Bebulin Benefix Corifact DDAVP (desmopressin acetate) (oral/nasal forms are not specialty) Eloctate TM Feiba NF Combivir * (lamivudine/zidovudine) Complera * Crixivan * Edurant * Egrifta Emtriva * Epivir * (lamivudine) Epzicom * (abacavir/lamivudine) Evotaz TM * Fuzeon * Intelence * Invirase * Isentress * Kaletra * Lexiva * Norvir * Prezcobix TM * Prezista * Rescriptor * Retrovir * (zidovudine) Reyataz * Sustiva * Tivicay * include Novarel, Pregnyl ) Crinone Endometrin Follistim AQ Ganirelix (ganirelix acetate) Gonal-F leuprolide Menopur Ovidrel progesterone injection (oral forms are not specialty) Repronex INFLAMMATORY CONDITIONS Actemra Arcalyst Benlysta Cimzia Cosentyx TM Enbrel Entyvio TM
4 Unless otherwise noted, all brand and generic formulations of a product are considered specialty. Green = Drugs distributed exclusively by Accredo. Red = Drugs distributed by Accredo as part of a limited distribution network. Blue = Drugs that are designated specialty but not dispensed by Accredo. * = Your plan may require most specialty medications to be dispensed exclusively by Accredo. Those medications marked by an asterisk (*) may have allowances for one or more retail fills. INFLAMMATORY CONDITIONS (cont d) Humira Humira (Pediatric) Ilaris Kineret Krystexxa Orencia Otezla Remicade Simponi TM Simponi Aria Stelara TM Xeljanz IRON TOXICITY Jandenu TM Exjade Ferriprox MISCELLANEOUS SPECIALTY CONDITIONS Acthar H.P. Gel Apokyn Arestin Botox Botox Cosmetic Ceprotin TM Chenodal Cholbam Cystadane Cystagon Dysport Evzio Gattex Hetlioz TM Juxtapid Kynamro TM Makena TM Myalept TM Myobloc Northera TM Prialt Procysbi TM Qutenza Ravicti TM Sabril Solesta Soliris Sprix Varithena Vivitrol Xenazine Xeomin Xiaflex TM Xyrem Zecuity MULTIPLE SCLEROSIS Ampyra TM Aubagio Avonex Betaseron Copaxone Duopa TM Extavia Gilenya TM Lemtrada TM mitoxantrone Plegridy TM Rebif Tecfidera TM Tysabri OPHTHALMIC CONDITIONS Cystaran TM Eylea Iluvien TM Jetrea Lucentis Macugen Ozurdex TM Retisert Visudyne OSTEOARTHRITIS Euflexxa Gel-One Hyalgan Monovisc Orthovisc Supartz Synvisc OSTEOPOROSIS Boniva (ibandronate) (oral forms are not specialty) Forteo Prolia TM Reclast PULMONARY HYPERTENSION Adcirca Adempas Flolan Flolan Diluent Letairis Opsumit Orenitram TM Remodulin Revatio (sildenafil citrate) Tracleer Tyvaso Veletri Ventavis RESPIRATORY SYNCYTIAL VIRUS Synagis * TRANSPLANT Astagraf XL TM * Cellcept * (mycophenolate mofetil) Cyclosporine (Sandimmune *, Neoral, Gengraf ) Imuran *, (Azasan *, azathioprine) Myfortic * (mycophenolic acid) Nulojix * Prograf *, (Hecoria TM *, tacrolimus. Topical forms are not specialty) Rapamune * (sirolimus) Simulect * Thymoglobulin * Zortress *
5
April 2015 NALC Specialty Pharmacy Drug List Providing one of the broadest offerings of specialty pharmaceuticals in the industry
NALC Specialty Pharmacy Drug List Providing one of the broadest offerings of specialty pharmaceuticals in the industry The NALC Specialty Pharmacy Drug List is a guide of medications available through
More informationJanuary 2018 Updated 12/01/2017 Advanced Control Specialty Formulary
January 2018 Updated 12/01/2017 Advanced Control Specialty Formulary The CVS Caremark Advanced Control Specialty Formulary is a guide within select therapeutic categories for clients, plan members and
More informationPrior Authorization and Voluntary Preservice Determination Requests for Certain Pharmacy Drugs
October 2016 Prior Authorization and Voluntary Preservice Determination Requests for Certain Pharmacy Drugs Important Changes We want to let you know that on November 14, 2016, we will change prior authorization
More informationMEDICATION AUTHORIZATION WORKFLOW FOR DRUGS THAT REQUIRE PRIOR-AUTHORIZATION (03/23/18) BASED ON LOCATION WHERE DRUG WILL BE ADMINISTERED
J9264 Injection, paclitaxel protein-bound particles, 1 mg ABRAXANE J3262 Injection, tocilizumab, 1 mg ACTEMRA J0800 Injection, corticotropin, up to 40 units ACTHAR HP J9042 Injection, brentuximab vedotin,
More informationSpecialty drug coverage
Specialty drug coverage For members with the Aetna Value plan, Value Plus plan and Premier plan 2017 Aetna Specialty Drug List 54.03.439.1 C (7/17) aetna.com You may get your first fill of these drugs
More informationSpecialty drug coverage
Specialty drug coverage For members with the Aetna Premier Plus plan 2018 Aetna Specialty Drug List 05.03.429.1 E (9/17) aetna.com You may fill these drugs at an in-network specialty pharmacy, like Aetna
More informationSpecialty drug coverage
Specialty drug coverage For members with the Aetna Value plan, Value Plus plan and Premier plan 2018 Aetna Specialty Drug List 05.03.439.1 H (9/17) aetna.com You may get your first fill of these drugs
More informationAll of Colorado HealthOP's networks use the Cigna Performance product for our prescription drug coverage.
All of Colorado HealthOP's networks use the Cigna Performance product for our prescription drug coverage. Please see the Cigna Specialty Pharmacy Drug List below for the speciality prescription drug list
More informationPrior Authorization Drug List
Prior Authorization Drug List Most prescriptions are filled right away when you take them to the pharmacy. But some drugs need to be reviewed by your health plan before they re covered. This process is
More informationCLOTTING FACTOR REPLACEMENT THERAPY
CLOTTING FACTOR REPLACEMENT THERAPY Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage
More informationPremium Prior Authorization
Premium Prior Authorization Some medications must be authorized for coverage because they re only approved or effective in treating specific illnesses, they cost more or they may be prescribed for conditions
More informationSan Francisco Health Service System
San Francisco Health Service System Pharmacy Trends Board Forum: November 10, 2016 Prepared by: Aon s Pharmacy Point of View We Believe Getting patients to the RIGHT drug at the RIGHT channel for the RIGHT
More informationProcedures, programs and drugs you must precertify
Procedures, programs and drugs you must precertify Participating provider precertification list Starting April 1, 2018 Applies to: Aetna plans, except Traditional Choice plans All health benefits and insurance
More informationClotting Disorder Therapy
Last Review Date: October 13, 2017 Number: MG.MM.PH.25b Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationCENTENE PHARMACY THERAPEUTICS COMMITTEE THIRD QUARTER 2017 CLINICAL POLICY (BIOPHARM) SUMMARY TABLE Coverage Guideline/Policy &
Coverage Guideline/Policy & Status Revision Summary Description Procedure CP.PHAR.14 Hydroxyprogesterone Caproate (Makena/compound) No criteria changes. Added compound to the title. Background section
More informationContinued Development of Approved Biological Drugs
Continued Development of Approved Biological Drugs A Quantitative Study of Additional Indications Approved Postlaunch in the United States White Paper December 2007 Maya Said Charles-André Brouwers Peter
More informationParticipating provider precertification list
Participating provider precertification list Procedures, programs and drugs you must precertify Effective March 1, 2018 For additional information, read all general precertification information. Applies
More informationFuture strategies for pricing and market access in oncology
Future strategies for pricing and market access in oncology Discussion document October, 2014 BOSTON CHICAGO DALLAS DENVER LOS ANGELES MENLO PARK MONTREAL NEW YORK SAN FRANCISCO WASHINGTON Agenda We review
More informationANTHEM BLUE CROSS REIMBURSEMENT POLICIES AND MCKESSON CLAIMSXTEN RULES
ANTHEM BLUE CROSS REIMBURSEMENT POLICIES AND MCKESSON CLAIMSXTEN RULES Overview This document provides all new, revised and existing Policies and all new, revised and existing claims editing rules administered
More informationCLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS
UnitedHealthcare Commercial Medical Benefit Drug Policy CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS Policy Number: 2018D0047K Effective Date: January 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE...
More informationResearch Brief. Findings From HSC NO. 22, APRIL Limited Options to Manage Specialty Drug Spending
Research Brief Findings From HSC NO. 22, APRIL 2012 Limited Options to Manage Specialty Drug Spending BY HA T. TU AND DIVYA R. SAMUEL Spending on specialty drugs typically high-cost biologic medications
More informationNovel strategies for antibody discovery and optimization
Novel strategies for antibody discovery and optimization Rene Hoet, Biologics, Head of Antibody Lead Discovery rene.hoet@bayer.com, Berlin, February 1, 2016 Agenda Biologics at Bayer Success and Future
More informationCompanies Perspective on Biosimilars
Companies Perspective on Biosimilars Pharma Delegate Healthcare Seminar, 1 st July 2016 American Club, Tokyo, Japan Hideaki Nomura FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd. Agenda Why Biosimilars? Current
More informationAccess Delayed, Access Denied 2012
Studies in HEALTH POLICY April 2012 Access Delayed, Access Denied 2012 Waiting for New Medicines in Canada by Mark Rovere and Brett J. Skinner Key findings On average, Canadians wait over two years for
More informationCDER New Drug Review: 2014 Update
CDER New Drug Review: 2014 Update John K. Jenkins, M.D. Director, Office of New Drugs Center for Drug Evaluation and Research FDA/CMS Summit December 11, 2014 Slides posted at: http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproduct
More informationForm 2043 R3.0: Multiple Sclerosis Pre-HSCT data
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: EBMT Center Identification Code (CIC): Today's Date: - - Date of HSCT for which this form is being completed: -
More informationUnderstanding Biosimilars and Projecting the Cost Savings to Employers Update
Understanding Biosimilars and Projecting the Cost Savings to Employers Update Prepared by: Milliman, Inc. Frank Kopenski Jr, ASA, MAAA Principal and Consulting Actuary Katie Holcomb, FSA, MAAA Actuary
More informationCIBMTR Center Number: CIBMTR Recipient ID: RETIRED. EBMT Center Identification Code (CIC): Today s Date:
Multiple Sclerosis Pre-HSCT Data EBMT Center Identification Code (CIC): Today s Date: Sequence Number: Date Received: Registry Use Only Date of HSCT for which this form is being completed: & 20 20 HSCT
More information2016 OptumRx Trend Insights
2016 OptumRx Trend Insights TREND SUMMARY Overall trend summary This report offers our perspective of the forces driving trend and spending for 2015 vs. 2016. We define trend as growth in year-over-year
More informationMeridian Health Plan Pharmaceuticals Billed Under the Medical Benefit
0129 Abatacept 0586 AbobotulinumtoxinA 9264 Abraxane (paclitaxel protein bound) 3262 Actemra (tocilizumab) 0800 Acthar Gel 0135 Adalimumab 9287 Adcetris (brentuximab vedotin) 2046 Aflibercept 0180 Agalsidase
More informationUnderstanding the Prescription Drug Landscape & Best Practices for Managing the Benefit
Understanding the Prescription Drug Landscape & Best Practices for Managing the Benefit Diane Clausen Pharmacy Benefit Consultant Pharmaceutical Strategies Group, LLC 5360 Legacy Drive Building 3, Suite
More informationEvaluatePharma World Preview 2016, Outlook to 2022
EvaluatePharma World Preview 2016, Outlook to 2022 9th Edition September 2016 Welcome to the EvaluatePharma World Preview 2016, Outlook to 2022 The ninth edition of EvaluatePharma s World Preview brings
More informationMRC Technology. A Life Science Specialist Technology Transfer Company. Skaggs School of Pharmacy and Pharmaceutical Sciences, December 2011
MRC Technology A Life Science Specialist Technology Transfer Company Skaggs School of Pharmacy and Pharmaceutical Sciences, December 2011 Dr John Kelly, Associate Director Business Development John.kelly@tech.mrc.ac.uk
More informationThe Development of Therapeutic Monoclonal Antibody Products. A Comprehensive Guide to CMC Activities from Clone to Clinic Second Edition
The Development of Therapeutic Monoclonal Antibody Products A Comprehensive Guide to CMC Activities from Clone to Clinic Second Edition Acknowledgements BioProcess Technology Consultants gratefully acknowledge:
More informationPerspectives Spring The Drug Pipeline: What s in it and why it matters.
Perspectives Spring 2016 The Drug Pipeline: What s in it and why it matters. 2 The Drug Pipeline: What s in it and why it matters. Author: Mark Jackson, BScPhm, BComm, RPh Consultant Pharmacist, TELUS
More informationYour Prescription Drug [ or 20%] Plan with Refill By Mail
Refill By Mail The Home Delivery Pharmacy sends drugs you take on a regular basis right to your door. And you get a larger supply of medicine for less money. 1 Your Prescription Drug [15-40-75 or 20%]
More informationREAL WORLD EVIDENCE. Case Studies on Real World Evidence Impacting Payer Decisions
REAL WORLD EVIDENCE 2013 Case Studies on Real World Evidence Impacting Payer Decisions 1 Case Studies on Real World Evidence Impacting Payer Decisions INDEX BY COUNTRY CANADA... 2 FRANCE... 3 GERMANY....
More informationPHARMACY PROCUREMENT OF DRUG AND NON-DRUG PRODUCTS. Pharmacy Procurement of drug and non-drug products.
Page 1 of 11 SUBJECT: PURPOSE: POLICY: Pharmacy Procurement of drug and non-drug products. To establish the policy and procedures governing the procurement and control of pharmaceuticals and other supplies
More informationSovaldi Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.25 Subject: Sovaldi Pegasys Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Sovaldi Pegasys
More informationOutline. References. Marshall,1
Outline Multiple Sclerosis: More Than Your ABC s Janene L. Marshall, PharmD, BCPS Clinical Associate Professor Internal Medicine Clinical Pharmacist Chicago State University College of Pharmacy J-marshall@csu.edu
More informationOrphan Drug Development Strategic considerations
Orphan Drug Development Strategic considerations Jan van Emous Regulatory Affairs Director Europe PGH Genzyme, a Sanofi company www.genzyme.com jan.vanemous@genzyme.com Regulatory Intelligence Orphan Drug
More informationSpecialty Drug Spending
Specialty Drug Spending The IMS Institute for Healthcare Informatics reported that spending on specialty pharmaceuticals almost doubled from 2010 to 2015, and spending on this subset of drugs was responsible
More informationHemophilia A and B Recombinant Factor Replacement Therapy - 5EU Drug Forecast and Market Analysis to 2024
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Hemophilia A and B Recombinant Factor Replacement Therapy - 5EU Drug Forecast and Market Analysis to 2024 Hemophilia
More informationInvestor Presentation: Phase II Data for LCP Tacro. March 3, 2008
Investor Presentation: Phase II Data for LCP Tacro March 3, 2008 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. The words believe, expect, anticipate, intend, will, may,
More informationMASAC RECOMMENDATIONS CONCERNING PRODUCTS LICENSED FOR THE TREATMENT OF HEMOPHILIA AND OTHER BLEEDING DISORDERS (Revised April 2010)
MASAC Document #195 (Replaces Document #190) MASAC RECOMMENDATIONS CONCERNING PRODUCTS LICENSED FOR THE TREATMENT OF HEMOPHILIA AND OTHER BLEEDING DISORDERS (Revised April 2010) The following recommendation
More informationHemophilia A and B Recombinant Factor Replacement Therapy - Argentina Drug Forecast and Market Analysis to 2024
Hemophilia A and B Recombinant Factor Replacement Therapy - Argentina Drug Forecast and Market Analysis to 2024 Hemophilia A and B Recombinant Factor Replacement Therapy - Argentina Drug Forecast and Market
More informationLifeCycle Pharma A/S IMPROVING TREATMENTS IMPROVING LIVES. March 2011
LifeCycle Pharma A/S IMPROVING TREATMENTS IMPROVING LIVES March 2011 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. All statements other than statements of historical
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION March 2008 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. The words believe, expect, anticipate, intend, will, may, would, could and plan and similar
More informationUpdate on New MS Therapeutics
Update on New MS Therapeutics William Meador, MD Assistant Professor AAN August 2017 Meeting Disclosures Clinical Trial Involvement: SPRINT-MS Trial MediciNova, ibudilast LemCog Sanofi/Genzyme, alemtuzumab
More informationExposure to light is a concern with numerous
Hosp Pharm 2014;49(2):136 163 2014 Thomas Land Publishers, Inc. www.hospital-pharmacy.com doi: 10.1310/hpj4902-136 Special Feature Light-Sensitive Injectable Prescription s University of Illinois at Chicago
More informationBiosimilars in Clinical Practice: Formulary, interchange and substitution considerations (a European perspective)
Soul, September 14, 2017 Biosimilars in Clinical Practice: Formulary, interchange and substitution considerations (a European perspective) Vs17i13 Arnold G. Vulto PharmD PhD FCP Professor of Hospital Pharmacy
More informationDETERMINANTS OF ORPHAN DRUG PRICES IN FRANCE: REGRESSION ANALYSIS
DETERMINANTS OF ORPHAN DRUG PRICES IN FRANCE: REGRESSION ANALYSIS Korchagina D 1, Vataire AL 2, Toumi M 3, Falissard B 4, Aballéa S 2 ISPOR 18th Annual European Congress 1 University of Paris-Sud, Paris,
More informationTransitioning to Express Scripts
Transitioning to Express Scripts Welcome to Express Scripts. We re pleased to announce that, beginning January 1, 2017 the Michigan Tech prescription benefit will be managed by Express Scripts. Express
More informationVan monoklonale antilichamen tot nanolichamen: basisprincipes en technologie
Van monoklonale antilichamen tot nanolichamen: basisprincipes en technologie Prof. Paul Declerck Laboratorium voor Therapeutische en Diagnostische Antilichamen KU LEUVEN Monoklonale antilichamen Wie zijn
More informationHealth Care Logistics: an Enabler of Change BioLogistics in a Changing Healthcare World Northwestern University Transportation Center
Health Care Logistics: an Enabler of Change BioLogistics in a Changing Healthcare World Northwestern University Transportation Center Dave Bode VP, Health Care Solutions DSC Logistics April 20, 2016 Health
More informationFractionation Services and Recombinant Plasma Protein Products: Product Supply and Transitioning
Frequently sked uestions and Recombinant Plasma Supply and Transitioning Summary of product changes Red (underlined): not continuing Blue (bold): new Today s Product Mix Future Product Mix Product Size
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.44 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationPERSONALIZED MEDICINE AT FDA Progress Report
PERSONALIZED MEDICINE AT FDA 2017 Progress Report 2 2017 MILESTONES 1. Record number of personalized medicine approvals 2. Approval of first three gene therapies 3. First approval of tissue agnostic indication
More informationNordea. Hans Christian Teisen Executive Vice President and Chief Financial Officer. July 2008
Nordea Hans Christian Teisen Executive Vice President and Chief Financial Officer July 2008 FORWARD LOOKING STATEMENTS This presentation contains forward looking statements. The words believe, expect,
More informationBritish Journal of Clinical Pharmacology
Page 2 of 6 Are there any differences in the regulations of personalised medicine among the US, EU, and Japan? Rumiko Shimazawa, Masayuki Ikeda Graduate School of Biomedical Sciences, Nagasaki University
More informationCode: D: MM Department Policy. Code: D: MM Entity: Fairview Pharmacy Services. Department: Fairview Home Infusion
Department Policy Entity: Fairview Pharmacy Services Department: Fairview Home Infusion Manual: Policy and Procedure Manual Category: Home Infusion Subject: Administration of Medications - FHI Purpose:
More informationCOMMUNITY OUTREACH STRATEGIES
COMMUNITY OUTREACH STRATEGIES Program Overview & Strategies Table of Contents Program Overview & Strategies... 2,3 Best Practices... 4 Promotional Materials... 5 Sample Promotional Materials... 6,7 Frequently
More informationOrphan Drugs: Will they be Fostered by Biotech Alone?
Orphan Drugs: Will they be Fostered by Biotech Alone? Nabil Mouline, MBA, Consultant Michael Rice, MS, MBA, Consultant Defined Health s Insight Series Basking Ridge, NJ Basel, Switzerland Berlin, Germany
More informationBarriers towards uptake of Biosimilars and how to solve them. Separate facts from fiction.
Barriers towards uptake of Biosimilars and how to solve them. Separate facts from fiction. Prof. Arnold G. Vulto PharmD PhD FCP Hospital Pharmacist / Pharmacologist Professor of Hospital Pharmacy & Practical
More informationWebinar Series: Biosimilars
May 23, 2017 Webinar Series: Biosimilars Recent and Upcoming BPCIA Guidance from the Federal Circuit and the Supreme Court John Adkisson Principal Twin Cities Tasha Francis Associate Twin Cities Jenny
More informationApproval of a drug under this criteria document does not ensure full coverage of the drug.
Criteria Document: Reference #: PC/B006 Page 1 of 5 and Therapeutics Quality PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS)
More informationIndustry Surveys Biotechnology
Industry Surveys Biotechnology Steven Silver, Biotechnology Equity Analyst FEBRUARY 2013 Current Environment... 1 Industry Profile... 9 Industry Trends... 9 How the Industry Operates... 19 Key Industry
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Multiple Sclerosis Agents Page 1 of 17 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Multiple Sclerosis Agents Tysabri (natalizumab) and Lemtrada (alemtuzumab)
More informationOctober 23+24, Dr. Axel Herberg, CEO
Gerresheimer: Excellent prospects as a unique supplier to the Pharma & Life Science Industry Gerresheimer Capital Markets Day October 23+24, 2008 Dr. Axel Herberg, CEO 0 Disclaimer This presentation may
More informationCMS Reveals Plans to Test Lower ASP Add-On, Value-Based Strategies in Part B
Volume 13, Number 3 March 2016 News and Strategies for Managing High-Cost Specialty Products 3 4 5 6 8 9 10 Contents Trend Toward Separate Medical, Pharmacy Deductibles Grows More Hepatitis C Therapies
More informationWINNING BRAND VS. GENERIC COMPETITION
WINNING BRAND VS. GENERIC COMPETITION - Competition 2.0: Brands vs. Generics - Winning Beyond the Molecule www.bernardassociatesllc.com Innovator and generic companies are colliding as they invade each
More informationSpecialty Pipeline Update
Specialty Pipeline Update D Drug Insights > June 2016 New drug information Epclusa (sofosbuvir/velpatasvir): The Food and Drug Administration (FDA) approved Gilead s Epclusa for all forms of hepatitis
More informationMultiple Sclerosis Agents Drug Class Prior Authorization Protocol
Multiple Sclerosis Agents Drug Class Prior Authorization Protocol Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 This policy has been developed through review
More informationThe Data and Analytics of the New Life Sciences Marketplace 9 th International Pharmaceutical Compliance Congress and Best Practices Forum
The Data and Analytics of the New Life Sciences Marketplace 9 th International Pharmaceutical Compliance Congress and Best Practices Forum Dr. Frank Wartenberg President Central Europe 13. May 2015 Governments
More informationAAM Annual Meeting 2017
AAM Annual Meeting 2017 The US Pharmaceutical Market: Trends, Issues, and Outlook Doug Long VP Industry Relations QuintilesIMS Copyright 2016 QuintilesIMS. All rights reserved. Disclaimer The analyses,
More informationFDA Approves Teva Version of Neupogen; Uptake May Forecast Biosimilar Acceptance
Volume 9, Number 9 September 2012 News and Strategies for Managing High-Cost Specialty Products 4 5 7 8 9 11 12 Contents Experiences of Genentech, KV May Offer Lessons for Genzyme Allion Sells MOMS Pharmacy;
More informationRoche (ROG VX) EQUITY RESEARCH EUROPE
Switzerland Healthcare Pharmaceuticals Roche (ROG VX) TOGA Party: Opportunity In The Face Of Adversity Key Takeaway New product launches and indications are being underestimated for Roche whilst the fear
More informationHigh Cost Drugs Clinical Coding Standards and Guidance OPCS-4
High Cost Drugs Clinical Coding Standards and Guidance OPCS-4 Clinical Classifications Service Date 6 th March 2014 1 Copyright 2014, Health and Social Care Information Centre. Contents Introduction...
More informationThe Novel Drugs of 2014 Record Approvals for Niche Markets
Reddy et al: The Novel Drugs of 2014 Record Approvals for Niche Markets 2889 International Journal of Pharmaceutical Sciences and Nanotechnology Review Article The Novel Drugs of 2014 Record Approvals
More informationInstitutional Equities
Sector Update Institutional Equities Pharmaceutical Sector 19 June 2017 Enough Headroom To Grow For Indian Generic Companies Indian generic companies have scaled up their business in the US over the past
More informationFREQUENTLY ASKED QUESTIONS
FREQUENTLY ASKED QUESTIONS Preferred Home Delivery Program for Maintenance Medications 1. What are maintenance medications? Maintenance medications are prescription drugs that you need to take regularly.
More informationREPORT PHARMA THE TOP 20
THE TOP 20 PHARMA REPORT 2010 MM&M takes a look at the top 20 drug manufacturers and breaks down the sales data by company, prescription drugs and therapeutic class. We also track total promotional spend,
More informationSurvey 1 - Rheumatoid Arthritis (RA) Patients perception on originator biologics and biosimilars
SUPPLEMENTAL MATERIAL - Perception of originator biologics and biosimilars: a survey amongst Belgian rheumatoid arthritis patients and rheumatologists BioDrugs Eline van Overbeeke 1, Birgit De Beleyr,
More informationBIOSIMILAR ACCESS 17:40 18:00 17:15 17:25 17:25 17:40 18:00 18:15 OVERALL OBJECTIVE WORKSHOP GOALS
BIOSIMILAR ACCESS The Future of Value Assessment 1. HTA Workshop For Distribution to ISPOR Europe Attendees November 07, 2011 Cyrus A. Chowdhury Vice President and Practice Leader, Global Market Access
More informationEMA. François Houÿez. Director of Treatment Information & Access Eurordis Summer School 2012, Barcelona
Patients @ EMA François Houÿez Director of Treatment Information & Access Eurordis Summer School 2012, Barcelona Please comment (fictitious case) A pulmonary hypertension patients organisation collects
More informationNew Merck Hepatitis C Therapy May Spur Deeper Contracting on Price, Genotypes
Volume 13, Number 2 February 2016 News and Strategies for Managing High-Cost Specialty Products 3 4 6 7 8 9 12 Contents Generic Gleevec Should Lessen Costs for Rare But Costly CML Planning and Changes
More informationFDA Just Approved Some Highly Anticipated Specialty Drugs; Payers Must Prepare Now
FDA Just Approved Some Highly Anticipated Specialty Drugs; Payers Must Prepare Now By Angela Maas, Managing Editor April 2017Volume 14Issue 4 In late March, the FDA went on an approval tear, paving the
More informationMedicare Part B DME Infused Drugs Just Took Reimbursement Hit From Cures Act
Volume 14, Number 1 January 2017 News and Strategies for Managing High-Cost Specialty Products 4 5 6 6 8 9 12 Contents CMS Reverses Course, Drops Push for Part B Drug Payment Model New FDA Specialty Approvals
More informationCreating the global leader in Rare Diseases
Creating the global leader in Rare Diseases Fourth quarter and full year results to December 31, 2015 4 Flemming Ornskov, M.D. CEO Jeff Poulton CFO Phil Vickers, Ph.D. Head of R&D February 11, 2016 SAFE
More informationELECTRONICALLY REPRINTED FROM JUNE 2017 WHERE BUSINESS MEETS POLICY VOLUME 37, NUMBER PHARM EXEC 50 DARERS OF DISRUPTION
WWW.PHARMEXEC.COM ELECTRONICALLY REPRINTED FROM JUNE 2017 WHERE BUSINESS MEETS POLICY VOLUME 37, NUMBER 6 2017 PHARM EXEC 50 DARERS OF DISRUPTION Pharma 50 Pharmaceutical executive June 2017 /shutterstock.com
More informationACTELION S COMPANY PROFILE
ACTELION S Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs. The company
More informationClinical Policy: Multiple Sclerosis Reference Number: CP.CPA.206 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.206 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationCharacterization of Critical Reagents for Ligand Binding Assays
03_app_fly_Application Text Placeholder Ligand binding assays are utilized throughout the large molecule drug development process. However their robustness, accuracy and reproducibility depend on the quality
More informationNew Drugs Approved in May 2017
New Drugs Approved in May 2017 Review Category Date No. New / Partial Oncology drugs May 18, 2017 1 Xalkori Capsules 200 mg Xalkori Capsules 250 mg (Pfizer Japan Inc.) Crizotinib Drugs with a new additional
More informationNational Drug Codes Requirement for UnitedHealthcare Community Plan. Calculating the Appropriate Number of National Drug Code (NDC) Units
National Drug Codes Requirement for UnitedHealthcare Community Plan Calculating the Appropriate Number of National Drug Code (NDC) Units National Drug Code Requirement Effective for claims with a date
More informationStrategic Report. Andy Glowalla, Lead Consultant Elizabeth Davis, Consultant J.R. Hall, Consultant
Strategic Report Andy Glowalla, Lead Consultant Elizabeth Davis, Consultant J.R. Hall, Consultant 19 April 2004 Genentech, Inc. / 2 Background History 3 Products 3 Research & Development 5 Pipeline 5 Manufacturing
More informationUpdate on Biosimilars
Update on Biosimilars From Fiction to Formulary Natalie Nguyen, Pharm.D. PGY1 Pharmacy Administration Resident Virginia Commonwealth University Health System Disclosures I have no disclosures or conflicts
More information